The European commission approves GSK’s drug Jemperli (dostarlimab), the anti-PD therapy drug approved for the advanced endometrial cancer.
Endometrial cancer is found in the uterus inner lining known as endometrium. This is the most common cancer that affects the female reproductive system and it is the sixth most prevalent cancer across the world
In 23 April 2021 GlaxoSmithKline had announced that European Commission had granted marketing approval for Jemperli , a programmed death receptor-1 (PD-1)-blocking antibody for use in women suffering from recurrent and advanced endometrial cancer who have progressed on or following prior treatment with a platinum containing regimen. This approval makes Jemperli the first anti-PD therapy drug available for endometrial cancer in Europe.
Endometrial cancer is found in the uterus inner lining known as endometrium. This is the most common cancer that affects the female reproductive system and it is the sixth most prevalent cancer across the world. Endometrial cancer has the highest rate of the MSI-H phenotype of all tumors. GSK is also studying Jemperli for endometrial cancer in combination with other therapeutic drugs for patients with solid tumors or metastatic cancer as they expand their oncology segment and increasing their portfolio.
Dr Hal Barron, Chief Scientific Officer and President R&D, GSK, said: “Women with recurrent endometrial cancer, or advanced disease that has progressed on or after chemotherapy, currently have limited treatment options and a poor prognosis. Today’s approval of dostarlimab means that for the first time in Europe, these women will have access to a new, innovative and much-needed therapy.”